ARQT Arcutis Biotherapeutics, Inc.
$31.68▼ -0.41%
Healthcare
Other
After hours
$31.50▼ -0.57%
Oct 27, 5:02 PM ET
Volume 2.22M
Avg Volume (10D) 2.68M
Key Metrics & Fundamentals
Market Cap
$3.98B
P/E Ratio
144.0
Div Yield
0.00%
52W Range
19.30 - 33.30
% vs 50 MA
20.37%
% vs 200 MA
25.88%
RSI-14
65.6
MACD Histogram
+0.4200
Beta (1Y vs SPY)
1.03
Free Cash Flow
$12.48M
Gross Rev
$129.86M
Gross Profit
$118.92M
EBITDA
$19.11M
COGS
$10.94M
Operating Exp
$102.49M
Operating Income
$16.43M
EBIT
$16.43M
Pretax Income
$15.15M
Net Income
$15.01M
EPS (Diluted)
0.11
Price & Volume History
Loading chart…
Recent News
Arcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
GlobeNewswire · Oct 27, 2026 4:00 PM ET
Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026
GlobeNewswire · Oct 21, 2026 4:00 PM ET
Arcutis Biotherapeutics (ARQT) Gets New Rating Uprgades from 2 Analysts; Shares Climb
Insider Monkey · Oct 19, 2026 10:37 PM ET
Clinical Data Update Could Shape The Case For Arcutis Biotherapeutics Stock
Simply Wall St. · Oct 19, 2026 7:21 PM ET
Arcutis Soars 12% as Guggenheim Lifts Target to $44 on “Growing Conviction” in 2027
TIKR · Oct 19, 2026 1:13 PM ET
2 Stocks That Could Soar in Q4
Motley Fool · Oct 12, 2026 7:05 AM ET
Arcutis Biotherapeutics (ARQT) Showcased Fresh ZORYVE Data, Is It Still 28% Below Fair Value?
Simply Wall St. · Oct 10, 2026 1:14 AM ET
Arcutis Biotherapeutics' Zoryve Shows Rapid Disease Clearance in Infant Atopic Dermatitis Trial
MT Newswires · Oct 9, 2026 11:13 AM ET
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical
GlobeNewswire · Oct 9, 2026 8:00 AM ET
Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
GlobeNewswire · Oct 6, 2026 8:19 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See ARQT's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.